PartnershipUpdated on 10 April 2026
SCOLI Portfolio — ScoliGEN & ScoliVIEW IVD tools for adolescent idiopathic scoliosis
About
EpiDisease is offering the first-ever precision diagnostic portfolio for Adolescent Idiopathic Scoliosis (AIS), combining a saliva-based genetic risk tool (ScoliGEN) with an AI-powered automated Cobb angle measurement platform (ScoliVIEW).
ScoliGEN is already commercially available as an LDT with 90% sensitivity, and ScoliVIEW has been peer-reviewed and published in The Spine Journal with an ICC of 0.97 across 484 radiographs from four tertiary hospitals.
CE-IVD certification is expected in 2026, with FDA discussions to follow. We are looking for out-licensing partners, distribution agreements, and established commercial players in diagnostics or medical imaging to scale these products globally in a $1.7B TAM where no competitor currently exists.
Organisation
Similar opportunities
Partnership
HIST — HistSHOCK & HistSHOCK CDx
James Webb
Chief Commercial Officer at EpiDisease SL
Valencia, Spain
Project cooperation
Student project work (Master and Bachelor Thesis)
Patrick Link
Professor für Produktinnovation at Hochschule Luzern
Luzern, Switzerland